This site is intended for health professionals only

Tocilizumab – a new biologic for rheumatoid arthritis


Tina Hawkins

Rheumatology Pharmacist, Leeds Teaching Hospital NHS Trust


Professor Paul Emery

Article continues below this sponsored advert
Cogora InRead Image
Explore the latest advances in clinical care at events delivered by renowned experts from CofE

President of European League Against Rheumatism, Arthritis UK Professor of Rhematology, University of Leeds, UK


Rheumatoid arthritis (RA) is a long-term, chronic, 

autoimmune condition characterised by inflammation of the synovial joints combined with a number of systemic features resulting from abnormal immune response and secondary inflammation.  Uncontrolled disease may result in significant morbidity and mortality.1 Early intervention with disease modifying anti-rheumatic drugs (DMARDs) is essential to prevent long term joint damage, reduce morbidity and improve the patient

Be in the know
Subscribe to Hospital Pharmacy Europe newsletter and magazine